Meeting
2021 ASCO Annual Meeting
A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
Authors
Rachel E. Sanborn
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR
Rachel E. Sanborn , Rodolfo Eduardo Bordoni , Gini F. Fleming , Mustafa Khasraw , Thomas Hawthorne , Lawrence J Thomas , Tracey Rawls , Diane C. Young , Philip Golden , Tibor Keler , Michael Jay Yellin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT04440943
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2585)
DOI
10.1200/JCO.2021.39.15_suppl.2585
Abstract #
2585
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Igor Tsaur
Poster
2022 ASCO Annual Meeting
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.
First Author: Gonzalo Tapia
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed